EMAIL THIS PAGE TO A FRIEND

Journal of pharmaceutical sciences

A fast and reliable empirical approach for estimating solubility of crystalline drugs in polymers for hot melt extrusion formulations.


PMID 24634063

Abstract

A novel empirical analytical approach for estimating solubility of crystalline drugs in polymers has been developed. The approach utilizes a combination of differential scanning calorimetry measurements and a reliable mathematical algorithm to construct complete solubility curve of a drug in polymer. Compared with existing methods, this novel approach reduces the required experimentation time and amount of material by approximately 80%. The predictive power and relevance of such solubility curves in development of amorphous solid dispersion (ASD) formulations are shown by applications to a number of hot-melt extrudate formulations of ibuprofen and naproxen in Soluplus. On the basis of the temperature-drug load diagrams using the solubility curves and the glass transition temperatures, physical stability of the extrudate formulations was predicted and checked by placing the formulations on real-time stability studies. An analysis of the stability samples with microscopy, thermal, and imaging techniques confirmed the predicted physical stability of the formulations. In conclusion, this study presents a fast and reliable approach for estimating solubility of crystalline drugs in polymer matrixes. This powerful approach can be applied by formulation scientists as an early and convenient tool in designing ASD formulations for maximum drug load and physical stability.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

284785
(S)-(+)-6-Methoxy-α-methyl-2-naphthaleneacetic acid, 98%
C14H14O3
1003009
Acetaminophen, United States Pharmacopeia (USP) Reference Standard
C8H9NO2
PHR1005
Acetaminophen, Pharmaceutical Secondary Standard; Certified Reference Material
C8H9NO2
I4883
Ibuprofen, ≥98% (GC)
C13H18O2
I7905
Ibuprofen, meets USP testing specifications
C13H18O2
PHR1004
Ibuprofen, Pharmaceutical Secondary Standard; Certified Reference Material
C13H18O2
I0020000
Ibuprofen, European Pharmacopoeia (EP) Reference Standard
C13H18O2
1335508
Ibuprofen, United States Pharmacopeia (USP) Reference Standard
C13H18O2
I110
Ibuprofen
C13H18O2
Y0000881
Ibuprofen for peak identification, European Pharmacopoeia (EP) Reference Standard
C13H18O2
I6657
Itraconazole, ≥98% (TLC)
C35H38Cl2N8O4
I7000000
Itraconazole, European Pharmacopoeia (EP) Reference Standard
C35H38Cl2N8O4
N8280
Naproxen, meets USP testing specifications
C14H14O3
46482
Naproxen, VETRANAL, analytical standard
C14H14O3
PHR1040
Naproxen, Pharmaceutical Secondary Standard; Certified Reference Material
C14H14O3
N0250000
Naproxen, European Pharmacopoeia (EP) Reference Standard
C14H14O3
1457301
Naproxen, United States Pharmacopeia (USP) Reference Standard
C14H14O3
N7634
Nifedipine, ≥98% (HPLC), powder
C17H18N2O6
N114
Nifedipine
C17H18N2O6
N0750000
Nifedipine, European Pharmacopoeia (EP) Reference Standard
C17H18N2O6
1463508
Nifedipine, United States Pharmacopeia (USP) Reference Standard
C17H18N2O6
PHR1290
Nifedipine, Pharmaceutical Secondary Standard; Certified Reference Material
C17H18N2O6
P0300000
Paracetamol, European Pharmacopoeia (EP) Reference Standard
C8H9NO2